IBM is "big blue"...this is what you get when you hire high school grads and surgical techs--a very shallow talent pool.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an alternative browser.
You should upgrade or use an alternative browser.
-
Make it like cafepharma, but for different industries. Learn more about CompanyUnderground
IBM is "big blue"...this is what you get when you hire high school grads and surgical techs--a very shallow talent pool.
Anonymous
Guest
Anonymous
Guest
?..this is what you get when you hire high school grads and surgical techs--a very shallow talent pool.
If you think for one second that a tech or high school grad with some brains and strong work ethic cannot do your job, you are an arrogant fool.
The "Medtronic to buy S&N" cry has been heard for years. I wish they would just get it over with already.
Anonymous
Guest
Anonymous
Guest
If you think for one second that a tech or high school grad with some brains and strong work ethic cannot do your job, you are an arrogant fool.
The "Medtronic to buy S&N" cry has been heard for years. I wish they would just get it over with already.
"some brains" is all it takes for those credentials...
Anonymous
Guest
Anonymous
Guest
The FDA is visiting this next week. I hope they have lots of questions.
Anonymous
Guest
Anonymous
Guest
Covidien or Snn..... Hmmm good choice Medtronic! SNN is the biggest joke
Anonymous
Guest
Anonymous
Guest
Covidien or Snn..... Hmmm good choice Medtronic! SNN is the biggest joke
Since Medtronic just laid out $43B for Covidien, a SNN merger doesn't look to promising. Another golden opportunity for SNN to better themselves wasted.
Anonymous
Guest
Anonymous
Guest
Feeling a little rejected right about now? Come on JNJ, we need you to step up!
Anonymous
Guest
Anonymous
Guest
Blatant stock price manipulation by people in London spreading rumors. How big of a bonus does the ceo get for the price going up? And how long does it have to stay up?
Follow the money… I wish someone was investigating this organization.
It's obvious now that the takeover of SNN was just a rumor by the SNN London office to inflate the stock or bluff Stryker into making an offer.
Anonymous
Guest
Anonymous
Guest
I've said this a million times - no one will ever buy SNN. We have a reputation.
Anonymous
Guest
Anonymous
Guest
What do you see the future of Snn than? With the big boys all teaming up, how will this company compete?
Anonymous
Guest
Anonymous
Guest
I've said this a million times - no one will ever buy SNN. We have a reputation.
I agree. we are a small player with a small market share that is declining. my crystal ball predicts we will be a pink sheet stock in the future. plus a division that has recent major FDA recall stopping sales. red head step child syndrome.
Anonymous
Guest
Anonymous
Guest
You're an idiot. The least of your problems is redhead and stepchild are both one word. Go back to scrubbing.
Anonymous
Guest
Anonymous
Guest
Thanks for the correction. Better get back to your cube and put some time into the think tank with new ideas that might clear the FDA.
Pink sheet stocks still trade. Nothing to be upset about.
Come up for air and look at the real world instead of putting your head in the sand 24/7. You might learn something hot shot.
Is the class action lawsuit against ortho still going on? Or is the FDA still kick'n in the nutz?
BoOm!
Pink sheet stocks still trade. Nothing to be upset about.
Come up for air and look at the real world instead of putting your head in the sand 24/7. You might learn something hot shot.
Is the class action lawsuit against ortho still going on? Or is the FDA still kick'n in the nutz?
BoOm!
Anonymous
Guest
Anonymous
Guest
You're an idiot. The least of your problems is redhead and stepchild are both one word. Go back to scrubbing.
A corporate guy that has no clue and has probably never been in the sales field.
Can you get me a pair of your rose colored glasses when you go to Walmart again?
Anonymous
Guest
Anonymous
Guest
You're an idiot. The least of your problems is redhead and stepchild are both one word. Go back to scrubbing.
A corporate guy that has no clue and has probably never been in the sales field.
Please get me a pair of your rose colored glasses when you go to Walmart again.
Anonymous
Guest
Anonymous
Guest
Smith & Nephew SN.LN -0.47% PLC has missed out on the bouquet again. Shares in the London-listed, Dublin-based maker of replacement joints dipped around 2% in morning trading Monday, after U.S. pacemaker specialist Medtronic Inc.MDT -1.12%said it was buying Smith & Nephew’s Dublin-based rival Covidien COV +16.98%PLC for $42.9 billion.
That removes a potential suitor for Smith & Nephew, which as a small player in a consolidating market has long been touted as a takeover target. Shares in the artificial joint maker have risen more than 20% this year on rumors of takeover interest, and with Medtronic out of the picture, the field has narrowed.
Still, Medtronic wasn’t the only eligible match. Stryker Corp.SYK +1.40%—another U.S. artificial-joint manufacturer—said last month it was in the preliminary stages of evaluating a deal for Smith & Nephew but didn’t intend to make a formal offer. Under U.K. takeover rules, Stryker is now prevented from making a bid until November, but can return sooner if a rival bidder emerges.
A number of companies that were looking at a deal to buy S&N rival Biomet Inc., whichZimmer Holdings Inc.ZMH -0.57% bought in April, are now reviewing other opportunities in the sector, said one senior health-care banker.
The Medtronic deal highlights Smith & Nephew’s possible tax advantages. Smith & Nephew’s U.K. listing could make it attractive for a U.S. firm looking to use cash trapped offshore, and to pursue a so-called inversion deal to relocate in a country with a more favorable corporate tax rate, as Medtronic is doing.
The top 10 U.S. medical-technology firms are sitting on around $63 billion in cash and short-term investments, much of which is likely offshore, Berenberg estimates.
The attractiveness of inversion deals has risen after the European Union said it was investigating ways in which U.S. firms use practices like transfer pricing—another way companies can sidestep high U.S. corporate taxes—to lower their tax burden.
Still, Smith & Nephew’s own 28.9% tax rate shows that such a move may be tricky for a buyer to achieve. And at 20 times next year’s forecast earnings, around a 33% premium to its orthopedic peers, its shares are still pricing in a lot of interest.
“SN’s premium valuation is currently supported by M&A,” Morgan Stanley analyst Michael Jungling said in a note to clients Monday, noting that it is rare for Smith & Nephew to trade at a premium to peers on a sustainable basis. Its investors still hear wedding bells ahead.
That removes a potential suitor for Smith & Nephew, which as a small player in a consolidating market has long been touted as a takeover target. Shares in the artificial joint maker have risen more than 20% this year on rumors of takeover interest, and with Medtronic out of the picture, the field has narrowed.
Still, Medtronic wasn’t the only eligible match. Stryker Corp.SYK +1.40%—another U.S. artificial-joint manufacturer—said last month it was in the preliminary stages of evaluating a deal for Smith & Nephew but didn’t intend to make a formal offer. Under U.K. takeover rules, Stryker is now prevented from making a bid until November, but can return sooner if a rival bidder emerges.
A number of companies that were looking at a deal to buy S&N rival Biomet Inc., whichZimmer Holdings Inc.ZMH -0.57% bought in April, are now reviewing other opportunities in the sector, said one senior health-care banker.
The Medtronic deal highlights Smith & Nephew’s possible tax advantages. Smith & Nephew’s U.K. listing could make it attractive for a U.S. firm looking to use cash trapped offshore, and to pursue a so-called inversion deal to relocate in a country with a more favorable corporate tax rate, as Medtronic is doing.
The top 10 U.S. medical-technology firms are sitting on around $63 billion in cash and short-term investments, much of which is likely offshore, Berenberg estimates.
The attractiveness of inversion deals has risen after the European Union said it was investigating ways in which U.S. firms use practices like transfer pricing—another way companies can sidestep high U.S. corporate taxes—to lower their tax burden.
Still, Smith & Nephew’s own 28.9% tax rate shows that such a move may be tricky for a buyer to achieve. And at 20 times next year’s forecast earnings, around a 33% premium to its orthopedic peers, its shares are still pricing in a lot of interest.
“SN’s premium valuation is currently supported by M&A,” Morgan Stanley analyst Michael Jungling said in a note to clients Monday, noting that it is rare for Smith & Nephew to trade at a premium to peers on a sustainable basis. Its investors still hear wedding bells ahead.